An acetylcholinesterase inhibition biosensor based on a reduced graphene oxide/silver nanocluster/chitosan nanocomposite for detection of organophosphorus pesticides

A sensitive electrochemical acetylcholinesterase (AChE) biosensor based on a reduced graphene oxide (rGO) and silver nanocluster (AgNC) modified glassy carbon electrode (GCE) was developed. rGO and AgNC nanomaterials with excellent conductivity, catalytic activity and biocompatibility offered an extremely hydrophilic surface, which facilitated the immobilization of AChE to fabricate the organophosphorus pesticide biosensor. Carboxylic chitosan (CChit) was used as a cross-linker to immobilize AChE on a rGO and AgNC modified GCE. The AChE biosensor showed favorable affinity to acetylthiocholine chloride (ATCl) and could catalyze the hydrolysis of ATCl. Based on the inhibition effect of organophosphorus pesticides on the AChE activity, using phoxim as a model compound, the inhibition effect of phoxim was proportional to its concentration ranging from 0.2 to 250 nM with a detection limit of 81 pM estimated at a signal-to-noise ratio of 3. The developed biosensor exhibited good sensitivity, stability and reproducibility, thus providing a promising tool for analysis of enzyme inhibitors and direct analysis of practical samples.

Microencapsulation of coupled folate and chitosan nanoparticles for targeted delivery of combination drugs to colon

Folate-chitosan nanoparticles, co-loaded with 5-fluourouacil (5-FU) and leucovorin (LV) and prepared by ionic gelation technology were physically microencapsulated by enteric polymer using a solvent evaporation method. Average particle size of the microencapsulated particles was in the range of 15 to 35 µm. High drug encapsulation efficiency was obtained for both 5-FU and LV in the microencapsulated particles. Both drugs were in amorphous state in the microencapsulated particles. By enteric coating, excellent pH-dependent release profile was achieved and no drug release was observed in simulated gastric and intestinal fluids. However, when the pH value reached the soluble threshold of Eudragit S-100, a constant and slow drug release was observed. The results indicated that these microencapsulated particles are a promising vehicle for selectively targeting drugs to colon in the chemotherapy of colon cancer.

Plasma assisted finishing of cotton fabric with chitosan

Chitosan is a natural and non-toxic polymer which can be used as a multifunctional, e.g. antimicrobial or anti-wrinkle, agent on cotton fabrics. However, due to the lack of strong bonding forces between two polysaccharides, chitosan coating on cotton has poor durability. To provide efficient and irreversible chitosan adsorption on cotton substrate, it is required to build appropriate binding sites and to activate the substrate material properly. For this purpose, plasma treatment can be a promising method as it can activate the surface of the cotton fabric and improve the adsorption of chemicals in a completely harmless procedure. In this study, we investigated the effect of atmospheric pressure plasma treatment on adsorption of chitosan onto the cotton fabric. The purpose of the study was to investigate to which extent adsorption of chitosan on cotton can be improved by helium plasma treatment. Fibre surface and adsorption of chitosan were characterized by X-ray Photoelectron Spectroscopy (XPS) and Fourier Transform Infrared (FTIR) spectroscopy. Changes in hydrophobicity of fabric`s surface and fibre morphology were evaluated using contact angle method and scanning electron microscopy (SEM), respectively. The results from XPS showed an increase in the C=O bonds on cotton fabrics oxydised by helium plasma treatmnets, confirming the formation of aldehyde groups in cellulose. The characteristic absorbance band of chitosan, amide II (N-H bending vibration) showed an enlargement for all fabrics treated with helium and chitosan, as assesed by FTIR. The absorbance peaks of CH2 stretching vibrations, which confirm chitosan existence, were stronger for all treated fabrics compared to the untreated control. While the plasma only treated fabric surface was very hydrophilic, the surface became hydrophobic after chitosan coating.

Ultra-small algal chitosan ocular nanoparticles with iron-binding milk protein prevents the toxic effects of carbendazim pesticide

AIM: To fabricate ultra-small algal chitosan nanoparticles (US CS NPs) for efficient delivery of bovine lactoferrin (bLf) to ocular tissues through topical administration to prevent carbendazim-induced toxicity. MATERIALS & METHODS: Rat eye model was used to evaluate the in vivo biodistribution the US CS NPs and bovine eye model was used for evaluating ex vivo biodistribution. Human lens epithelial cell line (HLEB-3) model was used to evaluate the in vitro toxicity, uptake mechanism and in vitro efficacy of the synthesized bLf-US CS NPs over carbendazim-induced ocular toxicity. RESULTS: The in vivo and ex vivo biodistribution results suggest that the ultra-small CS NPs efficiently internalize into the ocular tissues within 1 h after administering topically. Ultra-small algal nanocarriers to encapsulate bioactive antioxidant bLf protein and evaluated its potential in inhibiting carbendazim-induced human lens cell apoptosis and oxidative stress. CONCLUSION: US CS NPs could be explored for their potential for delivering various ocular drugs through topical administration for other eye diseases including cataract, glaucoma and age-related macular degeneration.

Development of drug-loaded chitosan-vanillin nanoparticles and its cytotoxicity against HT-29 cells

Chitosan as a natural polysaccharide derived from chitin of arthropods like shrimp and crab, attracts much interest due to its inherent properties, especially for application in biomedical materials. Presently, biodegradable and biocompatible chitosan nanoparticles are attractive for drug delivery. However, some physicochemical characteristics of chitosan nanoparticles still need to be further improved in practice. In this work, chitosan nanoparticles were produced by crosslinking chitosan with 3-methoxy-4-hydroxybenzaldehyde (vanillin) through a Schiff reaction. Chitosan nanoparticles were 200-250 nm in diameter with smooth surface and were negatively charged with a zeta potential of - 17.4 mV in neutral solution. Efficient drug loading and drug encapsulation were achieved using 5-fluorouracil as a model of hydrophilic drug. Drug release from the nanoparticles was constant and controllable. The in vitro cytotoxicity against HT-29 cells and cellular uptake of the chitosan nanoparticles were evaluated by methyl thiazolyl tetrazolium method, confocal laser scanning microscope and flow cytometer, respectively. The results indicate that the chitosan nanoparticles crosslinked with vanillin are a promising vehicle for the delivery of anticancer drugs.

Investigation of chitosan adsorption onto cotton fabric with atmospheric helium/oxygen plasma pre-treatment

In this study, the effects of helium or a helium/oxygen mixture atmospheric pressure plasma treatment on the adsorption of chitosan onto the cotton fabric were investigated. Fabrics were treated with plasma prior to a chitosan finishing process, whereby fabrics were surface coated using a pad/dry/cure method. Fourier transform infrared spectroscopy, scanning electron microscopy, X-ray photoelectron spectroscopy, surface energy analyser and contact angle measurements were used to investigate the changes on the cotton surface. Furthermore, antimicrobial activity of the cotton fabric was evaluated. The results showed that plasma pre-treatment enhanced the chitosan adsorption to the cotton surface through physical bonding and there was weak evidence of chemical bonding interactions. A combination of plasma and chitosan treatment did not show any significant differences on the antimicrobial properties compared to chitosan only treated fabric. Plasma treatment changed the fibres physically and enhanced the surface energy and thickness of chitosan distributed on the fibres.

Litigation by shareholders and directors: an empirical study of the Australian statutory derivative action

A number of countries have statutory derivative actions. They allow a shareholder to bring legal action on behalf of the company, typically where the company refuses or is unable to bring the action. The Australian derivative action was enacted in March 2000 to overcome inadequacies with the common law derivative action. In this article the authors present the results of an empirical study of all cases decided under the Australian statutory derivative action during its first 6 years of operation. The study provides insights into the way Australian courts have interpreted and applied this legal remedy. The authors evaluate the statutory derivative action in light of the reasons for its enactment. Issues discussed in the article include the role of shareholder litigation in corporate governance and the rationale for statutory derivative actions.